# US 10,864,192 B2 · Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,192 B2
- Document ID: US10864192B2
- Status: Granted
- Kind: B2
- Application number: 16/138,768
- Filed: 2018-09-21
- Published: 2020-01-16
- Granted: 2020-12-15
- Earliest claimed: 2016-01-15
- Assignees: Aristea Translational Medicine Corporation
- Applicants: Aristea Translational Medicine Corporation
- Inventors: Robert E. Becker
- Web page: https://patentgrep.com/patent/US10864192B2

## CPC

- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions and methods for mitigating a pathology following brain trauma or at least a portion of a cascade of a pathology associated therewith, including compositions and methods for treating concussion or preventing the onset of anecrotic cell death in neurons. Exemplary compositions for treating concussion include an active compound comprising one or more of: phenserine, a phenserine metabolite, a phenserine prodrug, or combinations thereof; and one or more pharmaceutically acceptable excipients. The one or more excipients can be combined with the active compound to form an extended, controlled-release medicament that delivers a therapeutic concentration of the active compound over a period of time. Exemplary methods include administering a therapeutic dose of the active compound and, optionally, a therapeutically acceptable dose of a second active compound, and, optionally, maintaining the therapeutic doses of the active and optional second active compounds at therapeutically effective concentrations over a period of time.

## Claims

### Claim 1

A method for treating a brain injury event, the method comprising:
administering an extended, controlled-release medicament to a patient subsequent to a brain injury event, the extended, controlled-release medicament comprising:
an active compound comprising one or more of: phenserine, a phenserine metabolite, a phenserine prodrug, or combinations thereof; and
one or more pharmaceutically acceptable excipients combined with the active compound to form the extended, controlled-release medicament; and
maintaining in the patient, over a period of time following the brain injury event, a therapeutically effective concentration of the active compound sufficient to:
(i) inhibit, attenuate, or prevent onset or progression of anecrotic or preprogrammed cell death in neurons following the brain injury event;
(ii) inhibit, attenuate, or prevent brain trauma-induced neurodegeneration and/or conditions resulting therefrom; and/or
(iii) reduce risk of developing a neurodegenerative disorder following the brain injury event.

### Claim 2 (depends on 1)

The method as in claim 1, wherein the brain injury event comprises one or more of: a mild traumatic brain injury, a moderate traumatic brain injury, a severe traumatic brain injury, a concussion, a sub-concussive injury, or combinations thereof.

### Claim 3 (depends on 1)

The method as in claim 1, wherein the period of time is greater than or equal to about 24 hours.

### Claim 4 (depends on 1)

The method as in claim 1, wherein the extended, controlled-release medicament provides for maintaining in the patient the therapeutically effective concentration of the active compound over the period of time.

### Claim 5 (depends on 1)

The method as in claim 1, wherein maintaining the therapeutically effective concentration of the active compound comprises:
(a) obtaining a biological sample from the patient, the biological sample comprising a bodily fluid selected from the group consisting of a blood sample, saliva, cerebrospinal fluid, and urine;
(b) assaying the biological sample for one or more of:
(i) concentration of the active compound and/or metabolite thereof;
(ii) acetylcholinesterase activity;
(iii) exosomes, exosomes with brain marker labels, or other components associated with preprogrammed cell death;
(iv) one or more of plasma derived neuroinflammatory cytokines, markers of oxidative stress, IL-1β, IL-6, C-Reactive Protein, TNF-α, AP-1, AP-2, markers of astrocyte injury and/or death, S-100B, NSE, NAP-2, UCTH L-1, UCTH L-2, Aβ42, tau, or p-tau; and
(v) failure of the blood-brain barrier;
(c) optionally, comparing assay results to values determined at baseline established prior to administering the extended, controlled-release medicament to the patient or prior to the brain injury event; and
(d) optionally, adjusting a dose or dosage of the extended, controlled-release medicament to provide the therapeutically effective concentration of the active compound.

### Claim 6 (depends on 5)

The method as in claim 5, wherein the blood sample comprises plasma and peripheral red blood cells and, optionally, other blood components and wherein acetylcholinesterase activity in the peripheral red blood cells indicates: (i) a brain concentration of the active compound and/or metabolites thereof; and/or (ii) total brain functional pharmacodynamic activity of the active compound.

### Claim 7

A method for inhibiting brain trauma-induced neurodegeneration and conditions resulting therefrom, the method comprising:
administering an extended, controlled-release medicament to a patient subsequent to a brain injury event, the extended, controlled-release medicament comprising:
an active compound comprising one or more of: phenserine, a phenserine metabolite, a phenserine prodrug, or combinations thereof; and
one or more pharmaceutically acceptable excipients; and
maintaining in the patient, over a period of time following the brain injury event, a therapeutically effective concentration of the active compound sufficient to:
(i) inhibit, attenuate, or prevent onset or progression of anecrotic or preprogrammed cell death in neurons following the brain injury event;
(ii) inhibit, attenuate, or prevent brain trauma-induced neurodegeneration and/or conditions resulting therefrom; and/or
(iii) reduce risk of developing a neurodegenerative disorder following the brain injury event.

### Claim 8 (depends on 7)

The method as in claim 7, wherein the brain injury event comprises one or more of: a mild traumatic brain injury, a moderate traumatic brain injury, a severe traumatic brain injury, a concussion, a sub-concussive injury, or combinations thereof.

### Claim 9 (depends on 7)

The method as in claim 7, wherein the period of time is greater than or equal to about 24 hours.

### Claim 10 (depends on 7)

The method as in claim 7, wherein maintaining in the patient a therapeutic dose of the active compound at therapeutically effective concentrations comprises:
(a) obtaining a biological sample from the patient;
(b) assaying the biological sample for one or more of:
(i) concentration of the active compound and/or metabolite thereof;
(ii) acetylcholinesterase activity;
(iii) exosomes, exosomes with brain marker labels, or other components associated with preprogrammed cell death;
(iv) one or more of plasma derived neuroinflammatory cytokines, markers of oxidative stress, IL-1β, IL-6, C-Reactive Protein, TNF-α, AP-1, AP-2, markers of astrocyte injury and/or death, S-100B, NSE, NAP-2, UCTH L-1, UCTH L-2, Aβ42, tau, or p-tau; and
(v) failure of the blood-brain barrier;
(c) optionally, comparing assay results to values determined at baseline established prior to administering the extended, controlled-release medicament to the patient or prior to the brain injury event; and
(d) optionally, adjusting the therapeutic dose of the active compound to provide the therapeutically effective concentration of the active compound.

### Claim 11

A method for inhibiting brain trauma-induced neurodegeneration and conditions resulting therefrom, the method comprising administering at least a daily dose of a composition to a patient subsequent to a brain trauma, the composition comprising:
an active compound comprising one or more of: phenserine, a phenserine metabolite, a phenserine prodrug, or combinations thereof; and
one or more pharmaceutically acceptable excipients, wherein the one or more pharmaceutically acceptable excipients are combined with the active compound to form an extended, controlled-release medicament that delivers the active compound over a period of time.

### Claim 12

A method for treating a brain injury event, the method comprising administering at least a daily dose of a composition to a patient subsequent to a brain injury event, the composition comprising:
an active compound comprising one or more of: phenserine, a phenserine metabolite, a phenserine prodrug, or combinations thereof; and
one or more pharmaceutically acceptable excipients, wherein the one or more pharmaceutically acceptable excipients are combined with the active compound to form an extended, controlled-release medicament that delivers the active compound over a period of time.

### Claim 13 (depends on 1)

The method of claim 1, further comprising administering the extended, controlled-release medicament to the patient prior to the brain injury event.

### Claim 14 (depends on 2)

The method of claim 2, further comprising administering the extended, controlled-release medicament to the patient prior to the brain injury event.

### Claim 15 (depends on 3)

The method of claim 3, further comprising administering the extended, controlled-release medicament to the patient prior to the brain injury event.

### Claim 16 (depends on 7)

The method of claim 7, further comprising administering the extended, controlled-release medicament to the patient prior to the brain injury event.

### Claim 17 (depends on 8)

The method of claim 8, further comprising administering the extended, controlled-release medicament to the patient prior to the brain injury event.

### Claim 18 (depends on 9)

The method of claim 9, further comprising administering the extended, controlled-release medicament to the patient prior to the brain injury event.

### Claim 19 (depends on 11)

The method of claim 11, further comprising administering the composition to the patient prior to the brain injury event.

### Claim 20 (depends on 12)

The method of claim 12, further comprising administering the composition to the patient prior to the brain injury event.